Education
About Us
Working with TipRanks
Follow Us
Telomir Pharmaceuticals, Inc. (TELO)
:TELO
TELO Stock Chart & Stats
$1.35
-$0.17(-3.74%)
At close: 4:00 PM EST
$1.35
-$0.17(-3.74%)
Day’s Range― - ―
52-Week Range$1.12 - $5.40
Previous CloseN/A
Volume44.80K
Average Volume (3M)509.93K
Market Cap
$48.48M
Enterprise ValueN/A
Total Cash (Recent Filing)$7.33M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.14
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding34,380,970
10 Day Avg. Volume243,310
30 Day Avg. Volume509,930
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)189.26
Price to Sales (P/S)0.00
P/FCF Ratio-24.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.31
Revenue Forecast (FY)N/A
Telomir Pharmaceuticals, Inc. News
TELO FAQ
What was Telomir Pharmaceuticals, Inc.’s price range in the past 12 months?
Telomir Pharmaceuticals, Inc. lowest stock price was $1.12 and its highest was $5.40 in the past 12 months.
What is Telomir Pharmaceuticals, Inc.’s market cap?
Telomir Pharmaceuticals, Inc.’s market cap is $48.48M.
When is Telomir Pharmaceuticals, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Telomir Pharmaceuticals, Inc.’s earnings last quarter?
Currently, no data Available
Is Telomir Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Telomir Pharmaceuticals, Inc.’s price is currently Overvalued.
Does Telomir Pharmaceuticals, Inc. pay dividends?
Telomir Pharmaceuticals, Inc. does not currently pay dividends.
What is Telomir Pharmaceuticals, Inc.’s EPS estimate?
Telomir Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Telomir Pharmaceuticals, Inc. have?
Telomir Pharmaceuticals, Inc. has 34,380,970 shares outstanding.
What happened to Telomir Pharmaceuticals, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Telomir Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in TELO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Telomir Pharmaceuticals, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
TELO Sentiment 70%
Sector Average 68%
Sector Average 68%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 8.9%
Last 30 Days ▼ 8.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.66%
12-Months-Change
Fundamentals
Return on Equity
-303.19%
Trailing 12-Months
Asset Growth
610.39%
Trailing 12-Months
Company Description
Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
Technical Analysis
Tempest Therapeutics
―
Verrica Pharmaceuticals
―
Lantern Pharma
―
CalciMedica
―
Century Therapeutics
―
Ownership Overview
―
Insiders
3.37% Mutual Funds
0.30% Other Institutional Investors
93.29% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---